Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

Core Insights - Harmony Biosciences will present new open-label extension data from the Phase 3 ARGUS trial for EPX-100 (clemizole hydrochloride) at the 2025 American Epilepsy Society Annual Meeting [1][2] - The ARGUS trial is currently enrolling participants, with poster presentations scheduled for December 8, 2025 [2] - EPX-100 is being developed for the treatment of Dravet syndrome and Lennox-Gastaut syndrome, targeting central 5-HT2 receptors to modulate serotonin signaling [2][3] Company Overview - Harmony Biosciences is focused on developing innovative therapies for rare neurological diseases, established in 2017 and headquartered in Plymouth Meeting, PA [4] - The company emphasizes a commitment to addressing unmet medical needs through novel science and community programs [4] Product Information - EPX-100 is administered orally twice a day in a liquid formulation and is based on a proprietary zebrafish drug screening platform [2] - Dravet syndrome, which EPX-100 targets, has an estimated incidence rate of 1 in 15,700 in the US and is primarily caused by SCN1A gene mutations [3]